Liz is retiring, for a second time! She helpfully stepped up when Simon left last year, but now she really needs to call it a day.
The Treasurer is critical to our work of raising awareness of ME and influencing service improvement, and is a key member of the WAMES team. No charity can operate without one!
If you can easily balance your personal finances and enjoy planning and budgeting, then please consider doing the same for WAMES. Any additional knowledge and skills you might need can be picked up along the way.
The role of the treasurer is to:
ensure that proper financial records and procedures are maintained so we know how much money we have received and how much we are spending
give the management committee an understanding of WAMES’ financial affairs and advise on budgets, funding needs etc.
Researchers need to increase study sizes and apply strict diagnostic criteria
Polish researchers report that the difficulties with diagnosing ME/CFS and ensuring all research participants have the same condition, can lead to inaccurate research results.
Misdiagnosis can skew results significantly in studies with fewer than 500 participants. If research uses only participants with self-reported ME/CFS and does not check the diagnosis against accepted diagnostic criteria, then the study size needs to increase to improve accuracy.
It is also difficult to determine if results apply to all patients if only a group are studied women, young, old etc. And it is important to check that healthy controls in a study are in fact healthy.
Research studies should therefore have a large number of participants over 500 or 1,000, which could be achieved through multi-centre studies OR care is taken through applying diagnostic criteria and laboratory tests to ensure the group has the same diagnosis.
Research abstract:
Misdiagnosis of myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) can occur when different case definitions are used by clinicians (relative misdiagnosis) or when failing the genuine diagnosis of another disease (misdiagnosis in a strict sense). This problem translates to a recurrent difficulty in reproducing research findings.
To tackle this problem, we simulated data from case-control studies under misdiagnosis in a strict sense. We then estimated the power to detect a genuine association between a potential causal factor and ME/CFS. A minimum power of 80% was obtained for studies with more than 500 individuals per study group. When the simulation study was extended to the situation where the potential causal factor could not be determined perfectly (e.g., seropositive/seronegative in serological association studies), the minimum power of 80% could only be achieved in studies with more than 1000 individuals per group.
In conclusion, current ME/CFS studies have suboptimal power under the assumption of misdiagnosis. This power can be improved by increasing the overall sample size using multi-centric studies, reporting the excluded illnesses and their exclusion criteria, or focusing on a homogeneous cohort of ME/CFS patients with a specific pathological mechanism where the chance of misdiagnosis is reduced.
Canadian researchers believe they have uncovered a way to tell the difference between people with ME, FM and both ME + FM. 11 miRNAs (microRNAs) are proposed as potential biomarkers.
microRNA is the name of a family of molecules that helps cells control the kinds and amounts of proteins they make. That is, cells use microRNA to help control gene expression.
Molecules of microRNA are found in cells and in the bloodstream.
Gene expression refers to whether a particular gene is making too much, too little or the normal amount of its protein at a particular time. OSU
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and fibromyalgia (FM) are two chronic complex diseases with overlapping symptoms affecting multiple systems and organs over time. Due to the absence of validated biomarkers and similarity in symptoms, both disorders are misdiagnosed, and the comorbidity of the two is often unrecognized.
Our study aimed to investigate the expression profiles of 11 circulating miRNAs previously associated with ME/CFS pathogenesis in FM patients and individuals with a comorbid diagnosis of FM associated with ME/CFS (ME/CFS + FM), and matched sedentary healthy controls. Whether these 11 circulating miRNAs expression can differentiate between the two disorders was also examined.
Our results highlight differential circulating miRNAs expression signatures between ME/CFS, FM and ME/CFS + FM, which also correlate to symptom severity between ME/CFS and ME/CFS + FM groups. We provided a prediction model, by using a machine-learning approach based on 11 circulating miRNAs levels, which can be used to discriminate between patients suffering from ME/CFS, FM and ME/CFS + FM. These 11 miRNAs are proposed as potential biomarkers for discriminating ME/CFS from FM.
The results of this study demonstrate that ME/CFS and FM are two distinct illnesses, and we highlight the comorbidity between the two conditions. Proper diagnosis of patients suffering from ME/CFS, FM or ME/CFS + FM is crucial to elucidate the pathophysiology of both diseases, determine preventive measures, and establish more effective treatments.
The WAMES website has been showing its age for years so we are relieved to be in a position now in 2023 to be able to upgrade it. This won’t happen overnight as it will take some time and energy to update the content and plan a new site. AND we need to raise the money to pay for it!
We invite you to join us in raising £1,500.
Our Volunteering Coordinator, Sharon Williams launched a couple of birthday fundraisers and so far has raised £200.
We have contacted a number of Welsh web designers skilled in WordPress and have been gobsmacked to receive quotes varying from £400 to £10,000!
The lower the price, the fewer functions are offered and the more work the WAMES team would have to contribute. Unfortunately our skills are few, but we will still have to learn some new concepts and terminology to communicate effectively with the designer.
By the end of the process we will hopefully know what is meant by menu mapping, SEO optimisation, plug-ins, navigation, cross browser compatibility, hosting, SSL certificates etc. but if we want an effective website it will be essential that someone else is in charge of making it all happen!
£1,500 will cover the design, build and launch of the new website with initial hosting and support plan costs and rebranding.
Two separate US studies have found significant differences in the gut microbiomes of people with ME/CFS compared to healthy people, although it was not possible to tell if they were a cause or consequence of ME/CFS. Researchers hope the findings will help to develop a diagnostic tool, interventions (dietary, probiotic, prebiotic, or synbiotic) and divide patients into sub-groups to better treat them.
The microbiome may weigh as much as five pounds. The bacteria in the microbiome help digest our food, regulate our immune system, protect against other bacteria that cause disease, and produce vitamins including B vitamins B12, thiamine and riboflavin, and Vitamin K, which is needed for blood coagulation. (University of Washington)
Jackson Laboratory study
Julia Oh’s study compared microbiome samples from people with both short-term ME/CFS (under 4 years; 74 patients) and long-term ME/CFS over 10 years; 75 patients) as well as 79 age- and sex-matched healthy controls. The investigators also looked at blood plasma samples.
There was less diversity found in patients with short-term disease fewer microbes known to be butyrate producers. Butyrate is important for protecting the integrity of the gut barrier and is also known to play an important role in modulating the immune system.
In contrast, the gut microbiomes had re-established in those with long-term disease and were more similar to the healthy controls. However, there were a number of changes in the metabolites in their blood plasma, including many of those related to the immune system. They also had differences in levels of certain types of immune cells compared with the healthy controls.
Highlights
Multi-‘omics identified phenotypic, gut microbial, and metabolic biomarkers for ME/CFS
Reduced gut microbial diversity and increased plasma sphingomyelins in ME/CFS
Short-term patients had more severe gut microbial dysbiosis with decreased butyrate
Long-term patients had more significant metabolic and clinical aberrations
Williams’s study looked at the microbiomes of 106 people with ME/CFS and 91 healthy controls that were matched for age, sex, geography, and socioeconomic status. It also looked at levels of microbial species in the stool. It didn’t include analysis of blood plasma, though this group has already published plasma metabolomics analyses elsewhere. It did look at metabolites in the stool, which demonstrated reduced levels of butyrate metabolites in ME/CFS.
Highlights
ME/CFS patients have substantial gut microbiome dysbiosis
Bacterial abundances, functions, SCFAs and species interactions deviate in ME/CFS
Reduced F. prausnitzii and E. rectale in ME/CFS may contribute to butyrate deficiency
Low F. prausnitzii abundance correlates with more severe fatigue symptoms in ME/CFS
Endothelial dysfunction and vascular homestasis in ME/CFS
A sub-study of the RituxME trial by Norwegian researchers found a problem in the blood vessels on the heart in a group of people with ME/CFS. Treatment with Rituximab caused a slight but significant improvement in symptoms within 18 months. They conclude that the vascular or circulatory system could play a role in ME/CFS.
Endothelial dysfunction is a type of non-obstructive coronary artery disease (CAD) in which there are no heart artery blockages, but the large blood vessels on the heart’s surface constrict (narrow) instead of dilating (opening). This condition tends to affect more women than men and causes chronic chest pain. (Stanford)
Endothelial dysfunction in ME/CFS patients, by Miriam Kristine Sandvik, Kari Sørland, Elisabeth Leirgul, Ingrid Gurvin Rekeland, Christina Særsten Stavland, Olav Mella, Øystein Fluge inPLoS One, 2023 Feb 2;18(2):e0280942 [doi: 10.1371/journal.pone.0280942]
Research abstract
Objective:
A few earlier studies have found impaired endothelial function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The present study investigated large-vessel and small-vessel endothelial function in patients with ME/CFS.
Study design:
The study was a substudy of the RituxME trial, a national, multicenter, randomized, double-blind, placebo-controlled phase III study on the effect of rituximab vs. placebo in ME/CFS patients in Norway.
Flow-mediated dilation (FMD) and post-occlusive reactive hyperemia (PORH) was measured at baseline and after 18 months of treatment in 39 patients and compared with healthy controls. Other outcome measures were symptom severity and various physical function measures.
Results:
ME/CFS patients had markedly reduced FMD compared to healthy controls at baseline (5.1% vs. 8.2%, p< 0.0001, adjusted for arterial diameter and sex), and significantly lower microvascular regulation measured by PORH than healthy controls (1354 PU vs. 2208 PU, p = 0.002).
There were no differences between the treatment and placebo groups in symptom changes or vascular measures. As a group, the ME/CFS patients experienced a slight, but significant improvement in clinical symptoms after 18 months. PORH, but not FMD, was similarly improved (1360 to 1834 PU, p = 0.028). There was no significant correlation between FMD and PORH.
There were non-significant tendencies towards associations between symptom severity/physical function measures and lower FMD and PORH, and a significant correlation between PORH and steps per 24 hours at baseline.
Conclusions:
ME/CFS patients had reduced macro- and microvascular endothelial function, indicating that vascular homeostasis may play a role in the clinical presentation of this disease.
The RituxME study team in Bergen, Norway have turned their attention to the little studied topic of gut symptoms in ME/CFS.
Key summary:
Gastrointestinal symptoms are common in ME/CFS, but there is a knowledge gap in the literature concerning gastrointestinal motility features and detailed symptom description.
In this study, patients with ME/CFS had signs of impaired gastric accommodation after a liquid meal.
Out of 20 patients, 15 patients reported fullness/bloating, 9 reported abdominal pain, and 7 reported nausea. The patients showed signs of visceral hypersensitivity on a drink test.
Gastrointestinal symptoms are common in ME/CFS, but there is a knowledge gap in the literature concerning gastrointestinal motility features and detailed symptom description.
Objective:
In this study, we aimed to characterize gastric motility and gastric symptoms in response to a liquid meal.
Methods:
We included 20 patients with ME/CFS with abdominal complaints who were recruited to a double-blind randomized placebo-controlled trial of Rituximab. The patients of this sub study were examined with an ultrasound drink test, and gastrointestinal symptoms were evaluated using the Rome III questionnaire and Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) questionnaire.
Results:
We found that patients commonly reported fullness/bloating (75%), abdominal pain (45%) and nausea (35%). Ultrasound measurements revealed lower proximal measurements of the stomach after a meal (p <0.01) and larger fasting antral area (p = 0.019) compared to healthy controls. The patients had a stronger symptomatic response to the liquid meal compared to healthy controls regarding epigastric pain, discomfort and nausea (p < 0.05). Ninety percent of the patients reported bowel movement frequencies within the normal range but scored high on bowel habit dissatisfaction and life disruption.
Conclusion:
The patients presented with fullness/bloating, nausea and epigastric pain, showed signs of impaired gastric accommodation and visceral hypersensitivity, showing that the gastrointestinal symptoms of ME/CFS patients are similar to functional dyspepsia.
The theme for World ME Day 2023 will be the hallmark symptom of ME: post-exertional malaise. The campaign is all about changing the narrative, so that globally people begin to understand this disease more accurately. That’s why our tagline this year is “ME: the disease where pushing harder can make you sicker”.
Our 21 member organisations and countless individuals will be collaborating across the globe to get this message out for May 12th.
We’re going to keep using the hashtag #LearnFromME, because we know the ME community has incredible knowledge and expertise to share, and everyone can #LearnFromME. Whether you are a health professional, a friend, a family member, a politician, a healthcare commissioner, or a member of the public: ME is a disease that we can and should learn from.
So what is post-exertional malaise, and why are we focusing on it?
Post-exertional malaise (PEM) is something that everyone with ME experiences.
It is a worsening of symptoms after physical, mental, or emotional exertion that would not have caused a problem before the illness and is the hallmark symptom of ME. For some patients, sensory overload (light and sound) can induce PEM. PEM intensifies the severity of symptoms and may last days, weeks, or permanently. The symptoms typically begin to worsen 12 to 48 hours after the activity or exposure.
When someone hears about ME, we want this key aspect of the disease to be the first thing that comes to mind.
This is the story of ME that needs to be known, and learnt from.
Long COVID means millions more are experiencing post-exertional malaise
Before the COVID-19 pandemic hit, there were between 17 and 30 million people living with ME worldwide. But now there are 65 million people living with long COVID, and half of those individuals are experiencing post-exertional malaise.
This means the number of people living with ME has likely doubled over the past 3 years.
ME: the disease where pushing harder can make you sicker
Our 21 member organisations spanning 14 countries are all getting behind World ME Day and the focus on post-exertional malaise for 2023.
We plan to:
Define the story of ME around this core worsening of symptoms
Connect and build alongside those with long COVID
Create resources to help everyone #LearnFromME and post-exertional malaise
Lobby decision-makers globally for more research and better education around post-exertional malaise
In the run up to May 12th we’ll be creating ways for you to share your story of post-exertional malaise, or learn about this core aspect of ME and the impact it has.
Disrupted immune signatures found in females with ME/CFS
US researchers found that female ME/CFS patients responded differently to an exercise challenge that stimulates PEM, compared to healthy females. They studied the RNA molecules in the cells (transcriptomics).
The ME/CFS patients did not show significant changes in gene expression, while the healthy patients did.
During the recovery period (commonly when PEM begins), the ME/CFS patients showed an abnormal immune and cellular response.
“The unique functional pathways identified provide a foundation for future research efforts into the disease, as well as for potential targeted treatment options.”
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, complex multi-organ illness characterized by unexplained debilitating fatigue and post-exertional malaise (PEM), which is defined as a worsening of symptoms following even minor physical or mental exertion.
Our study aimed to evaluate transcriptomic changes in ME/CFS female patients undergoing an exercise challenge intended to precipitate PEM. Our time points (baseline before exercise challenge, the point of maximal exertion, and after an exercise challenge) allowed for the exploration of the transcriptomic response to exercise and recovery in female patients with ME/CFS, as compared to healthy controls (HCs).
Under maximal exertion, ME/CFS patients did not show significant changes in gene expression, while HCs demonstrated altered functional gene networks related to signaling and integral functions of their immune cells.
During the recovery period (commonly during onset of PEM), female ME/CFS patients showed dysregulated immune signaling pathways and dysfunctional cellular responses to stress. The unique functional pathways identified provide a foundation for future research efforts into the disease, as well as for potential targeted treatment options.
A review of treatment harms to patients with ME/CFS
Psychologist and researcher Dr David F Marks believes that as there is growing evidence that ME/CFS and PASC have similar symptoms “it seems highly possible that the same therapeutic approaches will be offered to patients with PASC as have already been tried with patients with ME/CFS.
It is timely to review the evidence on the potential harms of such treatments, one of which is Graded Exercise Therapy (GET) and another that is often combined with GET, Cognitive Behaviour Therapy (CBT).
Despite the evidence of physiological and cellular abnormalities in ME and CFS, these approaches follow the biopsychosocial model (BPSM) claimed by the discredited Psychosomatic School to legitimize the use of CBT and GET for patients with ME/CFS .
A recent review concluded:
The evidence …suggests that none of these psychosomatic hypotheses is empirically supported. The lack of robust supportive evidence together with the use of fallacious causal assumptions, inappropriate and harmful therapies, broken scientific principles, repeated methodological flaws and an unwillingness to share data all give the appearance of cargo cult science.
The psychosomatic approach needs to be replaced by a scientific, biologically grounded approach to MUS/ME/CFS that can be expected to provide patients with appropriate care and treatments.
Patients with MUS/ME/CFS and their families have not been treated with the dignity, respect and care that is their human right. Patients with MUS/ME/CFS and their families could consider a class action legal case against the injuring parties.”
Read the paper for full conclusions and an overview of the work of: